Medicines Control Council approves Tarceva® in South Africa for treatment of non-small cell lung cancer

Authors

  • Editorial Office

Abstract

Thousands of South African lung cancer patients could now live longer and with improved quality of life if they receive Tarceva

 

® (erlonitib), a novel alternative to traditional chemotherapy, recently approved by the Medicines Control Council (MCC).

Downloads

Issue

Vol. 1 No. 2 (2009)

Section

Press Releases

License

South African Journal of Gynaecological Oncology (SAJGO) Copyright is held by South African Society of Gynaecologic Oncology (SASGO). Copyright of the articles is held by the authors. The work is licensed under a Creative Commons Attribution-Non-Commercial Works 4.0 South Africa License (CC BY NC). Material submitted for publication in the SAJGO is accepted provided it has not been published elsewhere. The SAJGO does not hold itself responsible for statements made by the authors. The opinions expressed in this publication are those of the authors. They do no purport to reflect the opinions or views of SASGO or its members.